MS BioNTech WKN: A2PSR2 ISIN: US09075V1026 Forum: Aktien User: Thekla

Ich kannte jemand muss es leider heissen 😢

Bauchspeicheldrüsenkrebs.... meine Güte, nachher macht mich Biontech noch arbeitslos. Genau mein Klientel

“Over the remainder of 2023 we do expect shares to trade mostly on COVID vaccine outlook. However, longer term we think that the company has assembled the most complete, well-rounded oncology pipeline in biotech,” Canaccord analysts wrote. The analysts noted BioNTech’s early clinical approaches including personalized cancer vaccines and CAR-T approaches, saying they offer the opportunity to transform cancer treatment. Meanwhile, recent M&A (such as the deal with DualityBio for ADCs and OncoC4 for a CTLA-4 antibody) offer potential improvements to more validated commercial mechanisms. “We like these additions for two main reasons,” the analysts highlighted. “As a company developing multiple combinable approaches to oncology, acquiring rights to combinable assets creates multiple synergies to the larger portfolio, and the shorter runway to meaningful commercial contribution.helps provide a clear long-term path to become a growing profitable and growing oncology company. Along with a Buy rating, Canaccord has a price target of US$203 on BioNTech stock, which is currently trading above $102 in New York.